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ABSTRACT 
Mastermind-like 1 (MAML1) is well characterized for its involvement in the 
Notch signaling pathway where it functions as a transcriptional co-activator and 
facilitates the degradation of the Notch intracellular domain (NICD).  MAML1 has 
recently been implicated as a multifunctional protein that interacts with a variety of other 
signaling pathways, including Wnt-β-catenin, NF-kB, and MEF2C (myocyte enhancer 
factor 2C).  MEF2C is a member of the family of transcription factors involved in muscle 
cell differentiation and proliferation.  MAML1 has previously been shown to activate 
MEF2C transcription.  Given that MAML1 is responsible for degradation of the NICD, 
we wanted to know if MAML1 could also induce degradation of MEF2C.  Here we show 
that full length MAML1 induces degradation of MEF2C.  MEF2C is not degraded when 
co-expressed with MAML1 deletion constructs, MAML1 1-301 and MAML1 Δ75-300, 
suggesting the entire c-terminus is needed for degradation.  In addition, treatment with 
the proteasome inhibitor MG132 stabilized MEF2C expression both in the absence and 
presence of MAML1 when compared to dimethyl sulfoxide (DMSO) controls.  Immuno-
preciptations of MEF2C in the presence of MAML1 with MG132 treatment showed an 
increase in the amount of ubiquitin detected. Serine 98 and 110 in MEF2C appear to be 
essential for ubiquitination.  In order to determine if S98 and S110 are required for 
MAML1 degradation of MEF2C, we cloned the double serine mutant MEF2C S98A 
S110A.  However, co-expression of the mutant with MAML1 still resulted in decreased 
protein levels.  Our results showed MAML1-induced degradation of MEF2C occurs 
through the proteasomal pathway and that S98 and S110 are not required for degradation. 
	 v	
TABLE OF CONTENTS  
INTRODUCTION............................................................................................................ 1 
  
  
LITERATURE REVIEW................................................................................................. 4 
   
Mastermind Family of Transcription Co-activators............................................. 4 
   
Mastermind-like 1’s Role in the Notch Signaling Pathway.................................. 5 
   
MAML1 Functions Across Multiple Signaling Pathways.................................... 6 
   
MEF2C Signaling................................................................................................. 8 
   
Ubiquitin- Proteasome Dependent Protein Degradation....................................... 11 
  
  
EXPERIMENTAL PROCEDURES................................................................................ 12 
   
Materials and Reagents......................................................................................... 12 
   
Generation of MEF2C Mutant plasmids............................................................... 13 
   
Maxi Prep Plasmid Purification............................................................................ 15 
   
Transfection of Mammalian Cells........................................................................ 16 
   
Degradation Assays.............................................................................................. 17 
   
MEF2C Immunoprecipitations (IP)...................................................................... 17 
   
SDS-PAGE Preparation and Western Blotting..................................................... 18 
   
Promoter Assays................................................................................................... 19 
  
  
RESULTS......................................................................................................................... 20 
  
Co-expression of MEF2C and Mastermind-like 1 Leads to Reduced MEF2C   
Protein Levels....................................................................................................... 20 
  
Both TADs of Mastermind-like 1 are Required for Degradation to Occur.......... 21 
	 vi	
  
Mastermind-like 2 and Mastermind-like 3 Elicit Varying Effects on MEF2C 
Protein Levels....................................................................................................... 
 
22 
  
MG132 Treatment Recovers MEF2C Protein Levels........................................... 24 
  
Detection of Ubiquitin on MEF2C....................................................................... 26 
  
Mastermind Does Not Induce Degradation of MEF2C in Colorectal Cancer   
Cells...................................................................................................................... 27 
  
MEF2C Mutants Do Not Prevent MAML1 Induced Degradation....................... 31 
  
Effects on MEF2C Target Promoter Activity....................................................... 31 
  
  
DISCUSSION................................................................................................................... 34 
  
  
REFERENCES................................................................................................................. 38 
  
  
 
 
 
 
 
 
 
 
 
 
 
	 vii	
LIST OF TABLES 
Table 1: Site-directed mutagenesis primer sequences……………………………... 13 
Table 2: Lipofectamine 2000 transfection cell density…………………………….. 16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 viii	
LIST OF FIGURES 
Figure 1.   Full length MAML1 reduces the half-life of MEF2C and results in 
decreased protein levels…………………………………………….. 
 
 
3 
Figure 2. Characteristic domains of mastermind-like co-activators………….. 
 
4 
Figure 3.    MAML1 induced degradation of MEF2C………………………… 
 
20 
Figure 4. MAML1 deletion construct deficient in TAD1 or TAD2…………... 
 
21 
Figure 5. Co-expression of MEF2C with MAML1 deletion constructs……… 
 
22 
Figure 6. MAML2 and MAML3 do not induce degradation of MEF2C……... 23 
Figure 7. MG132 treatment recovers MEF2C protein levels…………………. 
 
25 
Figure 8. Detection of ubiquitin on MEF2C treated with MG132……………. 
 
26 
Figure 9. MAML1 does not induce degradation of MEF2C in HCT116 cells.. 
 
28 
Figure 10. MAML1 deletion constructs are unable to induce degradation of 
native MEF2C………………………………………………………. 
 
 
29 
Figure 11. MAML2 and MAML3 are unable to induce degradation of MEF2C 
in HCT116 cells…………………………………………………….. 
 
 
30 
Figure 12. MAML1 can induce degradation of MEF2C S98A S110A………... 
 
31 
Figure 13. Effects on MEF2 target promoter activity………………………….. 
 
33 
 
 
 
 
 
 
 
 
	 ix	
ABBREVIATIONS 
APC/C:  Anaphase promoting complex/ cyclosome 
CBF-1: Centromere binding factor 1 
CBP: CREB binding protein 
CDC20: Cell division cycle 20 protein 
CDK8: Cyclin-dependent kinase 8 
CSL: CBF-1, suppressor of hairless, and Lag-1 
DMEM: Dulbecco’s Modified Eagles Medium 
DMSO: Dimethyl sulfoxide 
GAPDH:  Glyceraldehyde 3-phosphate dehydrogenase 
GSK3b: Glycogen synthase kinase-3 beta 
Hes1: Hairy and enhancer of split-1 
Hey1: Hes-related family BHLH transcription factor with YRPW motif 1 
IP: Immunoprecipitation 
MADS: MCM1, agamous, deficiens, and serum-response factor 
MAML:  Mastermind-like protein 
MAML1: Mastermind-like protein 1 
MAML2: Mastermind-like protein 2 
MAML3: Mastermind-like protein 3 
MEF2: Myocyte enhancer factor 2 
MEF2C: Myocyte enhancer factor 2C  
MRF: Myogenic regulatory factor 
	 x	
Mrf4: Myogenic regulatory factor 4 
Myf5: Myogenic factor 5 
NICD: Notch intracellular domain 
NF-kB: Nuclear factor kappa B 
RelA: V-Rel avian reticuloendotheliosis viral oncogene homolog A 
SDS-PAGE: Sodium dodecyl sulfate- polyacrylamide gel electrophoresis 
TAD: Transcription activating domain 
TCF: T cell factor 
Wnt: Wingless-type MMTV integration site family member 
 
 
 
 
 
 
 
 
 
 
 
	 1	
INTRODUCTION 
 Myocyte enhancer factor 2C (MEF2C) is a human transcription factor first 
identified for its importance in muscle cell differentiation (1, 2).  Recent studies have 
demonstrated MEF2C is an essential regulatory transcription factor associated with 
multiple developmental pathways and disease abnormalities (3–7).  MEF2C belongs to 
the MADS box family of transcription factors, which includes MEF2A-D.  These 
transcription factors are non-myogenic alone but, when expressed with other myogenic 
regulatory factors (MRFs), they elicit myogenic functions to allow the differentiation of 
mesenchymal stem cells to myofibers (1, 8).  
Previous studies have implicated Mastermind-like 1 (MAML1) as an important 
co-activator for MEF2C-mediated transcription (8).  Unlike MEF2C, MAML1 does not 
interact with DNA directly but associates with other essential DNA-binding transcription 
factors, allowing efficient transcription initiation.  MAML1 was originally identified as 
an essential co-activator for the Notch signaling pathway, where it associates with the 
Notch intracellular domain (NICD) and centromere-binding factor 1 (CBF-1) to allow 
initiation of Notch target genes such as Hes1, Hes5, and Hey1 (9).  MAML1 is also 
required to facilitate the turnover of NICD in the nucleus. MAML1 has been shown to 
interact with CDK8 and CBF-1 to facilitate the phosphorylation-dependent ubiquitination 
of NICD (10).  Notch target genes are generally implicated for their importance in growth 
and differentiation. Therefore, this additional regulatory step is crucial to keep expression 
under control.  Abnormalities in these signaling pathways have been shown to lead to 
various cancers (11, 12). 
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Based on MAML1’s known function in the Notch signaling pathway and the 
discovery of MAML1 as a co-activator for MEF2C, we wanted to know if MAML1 was 
capable of inducing degradation of MEF2C.  Preliminary results generated by our lab 
show MAML1 does induce MEF2C degradation and we sought to determine whether 
degradation was occurring through the ubiquitin-proteasome pathway or through 
lysosomal degradation.  Our lab demonstrated that MAML1 decreased the half-life of 
MEF2C by 80 minutes determined by cyclohexamide pulse chase (Figure 1 A, B) (13).  
Additionally, MEF2C protein levels were lower in the presence of MAML1 at time point 
zero of cylohexamide treatment, indicating that MAML1 has the ability to maintain 
reduced levels of MEF2C.  Our lab also previously found both transcriptional activation 
domains (TAD) of MAML1 are required for degradation to occur (Figure 1 C, D) (13). 
We hypothesized that MAML1 would facilitate the turnover of MEF2C through 
phosphorylation-dependent ubiquitination and target MEF2C to be degraded by the 26S 
proteasome.  In addition to identifying MEF2C’s degradation pathway, we hoped to 
determine the effects of MAML1-induced MEF2C degradation on MEF2 promoter 
activity. 
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Figure 1.  Full length MAML1 reduces the half-life of MEF2C and results in decreased 
protein levels.  (A) Cyclohexamide pulse chase of HeLa cells expressing MEF2C in the 
absence and presence of MAML1. (B) The half-life of MEF2C with and without 
MAML1, determined from cyclohexamide pulse chase data (A) and shown in minutes.  
(C) MEF2C expressed alone or with MAML1 or MAML1 deletion constructs. (D) 
Quantification of MEF2C protein levels shown in C and normalized to GAPDH.  
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LITERATURE REVIEW 
Mastermind Family of Transcription Co-activators 
Mastermind was first identified as a member of the Notch signaling pathway in 
Drosophila melanogaster.  Like many developmental genes, this pathway has remained 
conserved across many species (14).  The mammalian homolog to Drosophila 
mastermind is the mastermind-like (MAML) family, which is composed of three 
members, MAML1, MAML2, and MAML3 (Figure 2) (9, 15).  All members of the 
MAML family are characterized by the presence of one basic and two acidic amino acid 
domains.  The N-terminal basic domain, located within the first 14-78 amino acids in 
MAML1, is required for binding NICD and MEF2C (8, 15).  TAD1 begins directly after 
the basic domain at amino acid 79 to 300, while a region within TAD1 is required for 
binding of p300 and CREB-binding protein (CBP) (8, 15, 16).  The C-terminal TAD2 is 
required for promoter activation, though it is uncertain what co-factors interact with this 
region and are responsible for transcriptional activation (17). 
 
Figure 2.  Characteristic domains of mastermind-like co-activators.  The MAML family 
of transcriptional co-activators have two transcriptional activation domains TAD1 and 
TAD2.  MAML1, MAML2, and MAML3 all contain one basic and two acidic amino 
acid domains. 
TAD1 TAD
2 1 1153 
1 1133 
MAML1 
MAML2 
MAML3 
basic acidic 1 acidic 2 
14-78 214-282 1001-1016 
1 1016 
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Mastermind-like 1’s Role in the Notch Signaling Pathway 
Notch signaling is an evolutionarily conserved pathway essential for development 
and proliferation (18).  Abnormalities in this signaling pathway lead to disease 
progression, often resulting in the development of cancers (12).  Notch signaling is 
initiated when a Notch receptor on the surface of the receiving cell binds a Delta/Jagged 
ligand on the inducing cell.  This interaction between receptor and ligand initiates 
cleavage of the Notch intracellular domain (NICD) by γ-secretase.  This cleavage event 
releases NICD from the extracellular portion of the receptor, allowing it to translocate to 
the nuclease where it interacts with a CSL (CBF-1, Suppressor of hairless, and Lag-1) 
family member of transcription factors and MAML1 (10, 19, 20).  Assembly of the NICD 
transcriptional complex results in transcription of Notch target genes such as Hes1, Hey1 
(Hairy/enhancer of split), c-Myc, and p21 (10, 21–23).  Hes1 and Hey1 are primarily 
known to be transcriptional repressors important in neural development, while p21 is an 
important factor involved in cell cycle arrest (21–23).  Many of the known Notch target 
genes have been implicated in pathways involved in development and cell proliferation; 
therefore, it is essential that they be tightly regulated.  Uncontrolled Notch activity has 
been shown to lead to a variety of cancers (10, 20).  
MAML1 has been shown to be a co-activator for NICD and the corresponding 
CSL family of transcription factors by aiding in the recruitment of p300 (10).  In the 
absence of MAML1, transcriptional activity of NICD is drastically reduced.  However, 
reconstituted MAML1 significantly up regulates the transcription of the reporter gene 
(10, 19, 21).  Association of MAML1 with NICD and CBF-1 (a CSL transcription factor) 
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is responsible for activating Notch target transcription.  Specifically, the N-terminus of 
MAML1 is required for the interaction with the NICD, while the C-terminus is essential 
for the recruitment of remaining cofactors and activation of the transcriptional complex 
(16, 21). 
While MAML1 has been shown to significantly up regulate the activity of the 
Notch transcriptional complex, it has also been shown to be essential in regulating the 
turnover of NICD through a phosphorylation-dependent mechanism (10).  MAML1 and 
Cyclin-dependent kinase 8 (CDK8) work jointly to facilitate phosphorylation of NICD as 
a method to ensure tight regulation of Notch target genes (10).  Phosphorylation of NICD 
signals it for ubiquination by the ubiquitin ligase Fbw7 and proteasomal degradation (10, 
24).  Whether MAML1 activates the transcriptional complex or inhibits it through 
inducing NICD turnover appears to be dependent on the time elapsed following the initial 
transcription activation event (10, 24).  While this mechanism is not fully understood, 
research suggests MAML1 functions as an activator initially but later recruits CDK8 and 
facilitates turnover of the complex.  MAML1 regulation of NICD turnover is essential for 
maintenance of the signaling pathway.  This ensures that Notch target genes, known to 
play an important role in development and tissue differentiation, are tightly regulated; 
preventing consequences often associated with uncontrolled cell growth and proliferation. 
MAML1 Functions Across Multiple Signaling Pathways 
MAML1 has been implicated as an important co-factor in multiple signaling 
pathways, including Notch, MEF2C, Nuclear factor-kB (NF-kB), and Wingless-type 
MMTV integration site family member (Wnt)-b-catenin.  It has been suggested that 
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MAML1 may play an important role in maintaining communication and balance across 
these signaling pathways during developmental processes (8, 17, 25–28).  
MAML1 regulates the NF-kB signaling pathway through co-activation of RelA 
and induced degradation of the inhibitor IkBα.  NF-kB signaling is associated with many 
diverse functions including cell proliferation, inflammation, and innate and adaptive 
immune responses (27).  Regulation of this pathway is highly important for the 
prevention of many diseases such as arthritis, diabetes, cancer, and various viral 
infections (27, 29).  Degradation of the NF-kB inhibitor, IkBα, is essential for active NF-
kB signaling events.  MAML1 enhances NF-kB signaling by facilitating modifications in 
IkBα that lead to its ubiquitination (27).  Increased transcriptional activity of NF-kB 
target genes has not only been attributed to the degradation of IkBα but also to the 
interaction between MAML1 and the RelA subunit of NF-kB (27).  Evidence indicates 
MAML1 interacts with RelA, resulting in co-localization of MAML1 and NF-kB in the 
nucleus.  MAML1 causes the same pattern formation in the nucleus during Notch 
signaling and MEF2C activation, suggesting the formation of a transcriptional complex 
(8, 10, 27).  
MAML1 plays an important role in the Wnt-b-catenin signaling pathway as a co-
activator for b-catenin and the associated T-cell factor (TCF) transcription factor (30).  
Additionally, the Wnt signaling pathway up regulates the expression of MAML1 through 
the down regulation of GSK3β.  GSK3β is associated with inhibition of MAML1 
transcriptional activity through direct interaction.  Wnt signaling inhibits expression of 
GSK3β, resulting in the up regulation of MAML1 and increased transcriptional activity 
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of MAML1 target pathway (25).  The Wnt pathway has been implicated as a potential 
regulator of the crosstalk between Notch and various other signaling pathways through 
MAML1 regulation (25, 31).  In contrast, smaller niche environments, such as stem cells, 
show evidence that Wnt and Notch signaling pathways oppose each other (31).  This 
relationship has not been fully elucidated; however, the distribution of MAML1 may play 
an important role in the regulation of these pathways and their effects on cell 
proliferation. 
MEF2C Signaling 
MEF2C belongs to the Myocyte Enhancer Factor 2 (MEF2) family of 
transcription factors originally identified as muscle-specific genes due their up regulation 
during myoblast differentiation (1, 32).  MEF2 family contains four members, MEF2A-
D, which all contain two conserved domains, the MADS (MCM1, Agamous, Deficiens, 
and serum-response factor) box domain and MEF2 domain.  The MADS domain is 
located within the first 55 amino acids, while the MEF2 domain is located within the 27 
amino acids downstream of the MADS box (32).  The MEF2 protein domain is 
responsible for recognizing the AT rich sequence (CTA(A/T)4TAG) known as the MEF2 
element within the promoter E-box of target genes such as Myogenin, MyoD, and Desmin 
(1, 32, 33).  The MADS and MEF domains are responsible for allowing protein 
dimerization and DNA binding (8).  MEF2 proteins have been shown to bind their target 
promoter element as either homo or heterodimers dependent on the specific cell type.  
This variation in binding activity may influence the transcriptional effects on target gene 
expression (32, 34).  Other members of the MEF2 family are expressed ubiquitously, 
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while MEF2C is believed to be only highly expressed in skeletal muscle and the cerebral 
cortex (1, 2, 34). 
Skeletal muscle formation originates when undifferentiated myoblasts exit the cell 
cycle and fuse to form multinucleated myotubes.  This differentiation process is 
associated with the activation of muscle-specific genes, such as myogenic regulatory 
factors (MRFs), SRF, and MEF2.  Additionally, myogenesis relies on the down 
regulation of genes associated with growth and division (8, 33).  MRFs, including MyoD, 
myogenin, Myf5, and MRF4 form heterodimers with E proteins and interact with the E-
box region of a target gene.  Unlike MEF2 proteins, all MRFs have independent 
myogenic activity (8).  
MAML1 has been shown to be an essential co-activator for MEF2C both in 
overexpressed cell culture systems and during the myogenic differentiation profile.  
Research has proven that MAML1 knock out mice have drastically reduced survival rates 
and exhibit muscular dystrophy like symptoms.  The hallmarks of this knock out show 
significant decrease in size and weight, as well as severe alterations to skeletal muscle 
when compared to wild-type mice (8).  Mouse embryonic fibroblasts (MEFs) can be 
transduced with MyoD to differentiate into distinct myotubes.  However in MAML1 
knock out MEFs, this differentiation is unable to occur (8).  Shen et al. found a distinct 
correlation between the amount of MAML1 transduced in C2C12 cells and the reporter 
activation of an artificial MEF2 promoter.  Indicating MAML1 and MEF2C act 
cooperatively to activate gene expression.  Additionally MAML1 and MEF2C have been 
shown to co-localize in the nuclear foci formation that is indicative of NICD and 
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MAML1 in the nucleus (8, 10).  Similar to MAML1’s role in Notch signaling, both 
TAD1 and TAD2 are required for full activation of the MEF2C promoter.  Importantly 
when MAML1 and MEF2C are co-expressed there is a molecular weight shift in the 
western blot, indicating MAML1 may be inducing a post-translational modification on 
MEF2C (8). 
When Notch signaling is activated concurrent to MEF2C transcription, it results 
in a decrease of transcriptional activity to basal levels suggesting Notch has the power to 
sequester MAML1 for it’s own needs (8).  Interestingly, Notch signaling has been shown 
to both activate and inhibit myogenesis when activated at specific time points during 
differentiation (8, 35, 36).  Considering MAML1 regulates the turnover of NICD in the 
nucleus, we must examine the possibility of a similar function with MEF2C.  Minimal 
research has been done on this topic, however it has been shown that MEF2C 
transcriptional activity is tightly regulated but the involvement of MAML1 has yet to be 
discovered (37, 38). 
Recent research suggests MEF2C plays an important role in cell cycle regulation 
(37, 38).  MEF2C target genes are often involved in preventing cell proliferation due to 
their role in myogenesis and exit from the cell cycle.  Therefore, MEF2C must be 
degraded in order for cell proliferation to occur.  One study suggests Anaphase promoting 
complex/ Cyclosome (APC/C) ubiquitin ligase is responsible for regulating MEF2C 
levels allowing for cell cycle progression (37).  Badodi et al. shows a phosphorylation 
dependent mechanism allowing for MEF2C ubiquitiniation by APC/C relies on the 
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phosphorylation of serines 98 and 110 through a Cell division cycle 20 (CDC20) 
mechanism.  
Ubiquitin- Proteasome Dependent Protein Degradation 
The Ubiquitin-Proteasome pathway is closely associated with regulation of 
transcription factors in the nucleus.  Ubiquitin ligases have been shown to interact with a 
number of co-factors to facilitate the turn-over of transcriptional complexes, keeping 
gene expression under tight regulation (39).  One common mechanism of targeted 
ubiquitination is through modification of the substrate, usually in the form of 
phosphorylation (40).  Once the desired substrate has been identified by either 
phosphorylation or recognition of the degron, ubiquitin is covalently linked through a 
series of enzymatic reactions.  First the ubiquitin-activating enzyme (E1) transfers 
ubiquitin to the ubiquitin-conjugating enzyme (E2).  E2 then associates with the 
ubiquitin-ligase (E3) specific to the substrate and ubiquitin is covalently attached (41).  In 
mammalian cells, there are multiple variations of E2 and E3 enzymes, allowing for 
greater specificity during the protein degradation process.  Once the target protein has 
been ubiquitinated, it is then directed to the 26S proteasome for degradation.  This 
process is extremely important for regulating transcription, allowing for increased 
sensitivity to cellular signals while preventing the overexpression of genes needed for 
growth and proliferation (41, 42). 
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EXPERIMENTAL PROCEDURES 
Materials and Reagents 
HeLa cells and HEK-293 cells were purchased from American Type Culture 
Collection (ATCC).  HCT116 cells were obtained from the UCB Cell Culture Facility, 
supported by the University of California Berkeley.  All cell lines were maintained in 
Dulbecco’s Modified Eagles Medium (DMEM) containing 10% fetal bovine serum and 
1% antibiotic-antimycotic at 37 °C with 5% CO2 injection.  DMEM and 100X antibiotic-
antimycotic were purchased from Mediatech (Manassas, VA).  
Lipofectamine 2000, Opti-MEM, Protein A/G Magnetic Beads, LR Clonase, and 
100X Halt Protease Cocktail were purchased from Thermo Fisher Scientific (Waltham, 
MA).  Quickchange II XL Site-Directed Mutagenesis kit and XL10-Gold ultracompetent 
cells purchased from Agilent Technologies (Santa Clara, CA).  GenCatch Maxi Prep 
columns were purchased from Epoch Life Sciences (Missouri City, TX).  P1, P2, P3, 
QBT, and QF maxi prep buffers purchased from Qiagen (Hilden, Germany).  The Dual 
Luciferase Reporter Assay System and PureYield Plasmid Miniprep kit were purchased 
from Promega (Madison, WI). 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) buffers 
were prepared as follows: 4x lower buffer (375 mL of 2M Tris at pH 8.8, 10 ml of 10% 
SDS, 115 ml MilliQ H2O), 4x upper buffer (125 ml of 2M Tris at pH 6.8, 10 ml of 10% 
SDS, 365 ml of MilliQ H2O). 
Original MAM1 plasmids and mutant MAM1 constructs were prepared by Dr. J. 
Brandon White using Invitrogen’s Gateway technology.  The mastermind plasmids 
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(MAML1, MAML2, MAML3, MAML1 1-301, and MAML1 ∆75-300) were all cloned 
into the pCS2 6XMyc by Dr. J. Brandon White using Gateway technology.  HA-MEF2C 
was purchased from addgene as pcDNA3.1-MEF2C-HA.  Myc-MEF2C was cloned into 
the pCS2 6XMyc vector using Gateway Cloning Technology with LR Clonase. 
Imaging of all western blots was performed on the ImageQuant LAS4000, from 
GE Healthcare (Little Chalfont, UK).  Promoter assay readings were obtained using a 
Veritas Microplate Luminometer from Promega (Madison, WI).  All data analysis was 
done using Microsoft Excel and ImageQuant TL software. 
Generation of MEF2C Mutant plasmids 
MEF2C mutant constructs (S98A, S110A, and S98A S110A) were made in both 
the pcDNA3.1 and pCS2 backbone plasmids using the QuickChange II XL Site-Directed 
Mutagenesis kit.  Forward and reverse primers were designed to mutate both serine 98 
and serine 110 independently to alanine (Table 1).  Single mutant constructs were 
generated first and subsequently used as the DNA template for making the double mutant 
construct.   
Table 1: Site-directed mutagenesis primer sequences 
MEF2C Mutant Primer sequences 
MEF2C 
Mutant 
Forward primer 
S98A GGGCCTCAATGGCTGTGACGCCCCAGATCCCGATGCACAGACGATTC 
S110A GCAGACGATTCAGTAGGTCACGCCCCTGAGTCTGAGGACAAGTACAGG 
 
Following completion of the mutagenesis PCR, all samples were incubated with 1 
µL Dpn1 restriction enzyme at 37°C for 1.5 hours to digest methylated template DNA.  
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Samples were subjected to heat inactivation of the enzyme at 95°C for 5 minutes prior to 
transformation into XL10-Gold ultracompetent cells.  Two microliters of b-
mercaptoethanol (b-ME) was added to 40 µL of competent cells and incubated on ice for 
10 min.  Next, 5 µL of the PCR reaction was added to the b-ME/ competent cell mixture 
and incubated on ice for 30 min.  The transformation mixture was heat shocked at 42°C 
for 30 seconds and left on ice for 2 min.  Following transformation, the competent cells 
were recovered in NZY broth shaking at 225 rpm and 37°C for 1.5 h.  The transformation 
was then spun down and plated on LB-ampicillin plates and incubated at 37°C overnight.  
Following incubation of the site-directed mutagenesis transformation, colonies 
were picked and grown in 5 mL of LB-ampicillin broth overnight.  Cultures were then 
mini-prepped using the Promega PreYield Plasmid miniprep system.  Five hundred 
microliters of each culture was saved as a bacterial stock to maxi prep at a later time if 
mutagenesis was correct.   Five milliliter cultures were centrifuged at 3000 rpm for 5 
min.  Bacterial pellets were resuspended in 600 µL of Tris-EDTA (TE) and lysed by 
adding 100 µL of cell lysis buffer.  After inverting the tube to mix, lysis buffer was 
neutralized by adding 350 µL of neutralization solution and mixed by inversion several 
times.  All of the following centrifugation steps in this protocol occurred at maximum 
speed (16,000 rcf).  Samples were centrifuged for 3 min to pellet debris and the 
supernatant was transferred to the PureYield Minicolumn.  Columns were spun for 30 
seconds and the flow through was discarded.  The columns were washed with 200 µL of 
endotoxin removal wash and spun for 30 s.  Wash was discarded and the column was 
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washed again with 400 µL of column wash solution, column was spun for 30 s.  Again, 
the wash was discarded and the column was transferred to a clean 1.5 mL Eppendorf tube 
for elution.  Sixty microliters of sterile TE buffer was added to the membrane of the 
column and incubated at room temperature for 5 min.  The column was then spun for 30 s 
to elute DNA. 
Following preparation of the plasmids they were sent for sequencing analysis by 
Sequetech (Mountain View, CA) to confirm that mutagenesis was correct.  
Maxi Prep Plasmid Purification 
 Bacterial cultures were grown overnight at 37°C, shaking at 225 rpm.  Cultures 
were centrifuged the following morning at 5000 rpm for 10 min.  The pellets were 
resuspended in 10 mL of cold resuspension buffer (Qiagen Buffer P1) with RNase added.  
Ten mL of lysis buffer (Qiagen Buffer P2) was added and the tube was inverted 6-7 times 
to ensure complete lysis of all bacterial cells.  Lysis buffer was neutralized by adding 10 
mL of nuetralization buffer (Qiagen Buffer P3) and the tube was inverted until the 
mixture was homogenous.  Cell lysates were incubated on ice for 20 min prior to 
centrifugation at 15,000 rpm for 10 min at 4°C.  During centrifugation, Epoch columns 
were equilibrated with 30 mL of Qiagen Buffer QBT which was allowed to pass through 
the column by gravity flow.  Following centrifugation, the supernatant was poured into 
column and allowed to pass through by gravity flow.  Columns were then washed twice 
with 30 mL of Buffer QC and purified plasmid DNA was eluted with 15 mL of Qiagen 
Buffer QF. 
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 Plasmid DNA was precipitated by adding 12.5 mL of 100% isopropanol.  The 
tube was inverted several times to mix and centrifuged at 4°C and 15,000 rpm for 30 min.  
The supernatant was discarded and pelleted DNA was washed in 10 mL of ice cold 70% 
ethanol.  The DNA-ethanol mixture was then centrifuged at 4°C and 15,000 rpm for 30 
min.  Ethanol was discarded and the DNA pellet was allowed to air dry for 15 min.  
Purified plasmid DNA was then resuspended in 1 mL of sterile Tris-EDTA (TE) Buffer. 
Transfection of Mammalian Cells 
 Cells were plated 24 h prior to transfection at the cell density outlined in Table 2 
and maintained in complete DMEM.  Twenty-four hours after plating, DNA-lipid 
transfection mixtures were prepared and cells were transfected using Lipofectamine 
2000.  Plasmid DNA and Opti-MEM were mixed independently of the Lipofectamine 
2000: Opti-MEM master mix.  Both solutions were incubated at room temperature for 5 
min.  Next Lipofectamine 2000 master mix was aliquoted to the DNA-Opti-MEM 
mixture at a 1:1 ration and incubated at room temperature for 20 min.  During this 
incubation period, complete DMEM on cells is replaced with Opti-MEM.  The 
Lipofectamine transfection mixture was then added to each well.  Cells were collected 48 
h post-transfection. 
Table 2: Lipofectamine 2000 transfection cell density 
Plate 
Number of cells Lipofectamine 
2000 (µL):  
Opti-MEM (µL) 
Total [DNA] 
(ng/µL):  
Opti-MEM (µL) HeLa HEK-293 HCT116 
6 well 4x105 5x105 1x106 10 : 250 4000 : 250 
12 well 2x105 2.5x105 5x105 4 : 100 1600 : 100 
96 well -- 2.5x104 -- 0.5 : 25 200 : 25 
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Degradation Assays 
 Degradation of overexpressed MEF2C was tested by transfection MEF2C-HA in 
the absence and presence of MAML1.  In the case of proteasome inhibition, cells were 
treated with 10 µM MG132 or DMSO as a carrier control 24 h post transfection.  Cells 
were collected 48 h post transfection and analyzed via western blot.  MEF2C protein 
levels were analyzed by densitometry of the western blot and normalized to the 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) loading control for each sample.  
The density of the MEF2C alone sample was normalized to 100% and all other samples 
were represented as a percentage of the control.  Degradation assays of MEF2C were 
performed through co-expression of MAML1, MAML2, MAML3 and MAML1 deletion 
constructs MAML1 1-301, MAML1 D75-300. 
MEF2C Immunoprecipitation (IP) 
HEK293 cells were transfected with Myc-MEF2C, Myc-MAML1, HA-Ubiquitin 
and treated with 10 µM MG132 or DMSO as a carrier control 24 h post transfection.  
Twenty-four hours later samples are collected in RIPA buffer (50 mM Tris-Cl pH 7.9, 
150 mM NaCl, 1% NP-40, 0.5% DOC, and 0.1 % SDS) along with 1X halt protease 
cocktail.  Cell lysates were sonicated 3 times in 30 s pulses at 40% amplitude and 
centrifuged at 15,000 rpm for 5 min to remove cell debris.  Lysates were then transferred 
to clean tubes and 25 µL pre-washed Protein A/G Magnetic Beads in RIPA buffer were 
added.  Samples were pre-cleared with 5 µg rabbit IgG rotating at 4°C for 1 h.  Following 
pre-clearing, magnetic beads were removed from the sample using the magnetic tube rack 
and supernatants were transferred to a clean tube.  Five micrograms of Myc antibody was 
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added to each sample and allowed to rotate at 4°C overnight.  The following morning, 25 
µL pre-washed Protein A/G Magnetic Beads were added, and samples were rotated at 
4°C for 1 h to IP.  The samples containing beads were then washed three times for 5 min 
each, in RIPA buffer.  All RIPA buffer was removed from tubes and 75 µL 2X Laemmli 
buffer  (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% bromphenol blue and 
0.125 M Tris HCl pH 6.8) was added to each tube.  Tubes were placed on a 95ºC heat 
block for 7 min to denature the proteins and prepare samples for SDS-PAGE. 
SDS-PAGE Preparation and Western Blotting 
To prepare 10% SDS-PAGE gels the separating gel containing 2.5 mL 40% 
acrylamide, 2.5 mL 4X Lower buffer, 5 mL MilliQ water, 60 µL 10% Ammonium 
Persulfate (APS) and 15 µL TEMED, was poured and allowed to solidify for 30 min.  
Next the stacking gel was prepared with 525 µL 40% acrylamide, 1.25 mL 4X Upper 
buffer, 3.225 mL MilliQ water, 25 µL 10% APS and 6 µL TEMED.  The stacking gel 
was allowed to solidify for 1 h prior to usage or storage.  
Eight percent SDS-PAGE gels were used for IP experiments and made with the 
following modifications to the separating gel: 2.0 mL 40% acrylamide, and 5.5 mL 
MilliQ water were used.  All other reagents remained consistent. 
Western gels were run in the Mini-PROTEAN gel apparatus at 100 V for 15 
minutes, the voltage was then increased to 200 V for 45 min or until the dye front ran off 
the bottom of the gel.  To transfer SDS-PAGE gels to PVDF membrane, membrane was 
prepared by soaking in 100% methanol followed by soaking in transfer buffer.  Following 
set up of the transfer cassette, the transfer was run at 100 V for 1 h at 4°C.  Following 
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transfer, the membrane was blocked in 5% Dry Milk in TBS-T for 1 h.  The Blocking 
reagent was washed off in TBS-T and primary antibody was added at a dilution of 1:1000 
in 5% milk overnight.  The following day primary antibody was washed off 3 times for 
15 min each in TBS-T.  Species-specific secondary antibody conjugated to Horse radish 
peroxidase (HRP) were added to membranes at a dilution of 1:10,000 and rocked for 1.5 
h.  The secondary antibody was washed 3 times for 10 min each in TBS-T.  The protein 
molecular weight marker was then marked with pencil and the membrane was sprayed 
with ECL (HyGLO).  Western blots were imaged using the Image Quant imaging system. 
Promoter Assays 
 HEK293 cells were plated in a 96-well dish and transfected with the MEF2CLuc 
(MEF2C-Luciferase promoter), pRL-TK (renilla), MAML1, and MEF2C expression 
plasmids according to the protocol described above.  Samples were collected 48 h post 
transfection in 25 µL 1X Passive Lysis Buffer and shaken for 15 min.  Stop & Glo 
reagent (renilla) was prepared from 50X Stop & Glo substrate and Stop & Glo buffer.  
Luciferase reagent was prepared in advance and stored at -80°C to be thawed upon use.  
After cells were completely lysed, the luminescence was read on the luminometer under 
the following conditions:  50 µL Luciferase reagent, 50 µL Stop & Glo reagent, 5 sec 
delay between injection and measure, 10 sec integration time.  Firefly luciferase and 
renilla readings were obtained and analyzed using Microsoft Excel. 
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RESULTS 
Co-expression of MEF2C and Mastermind-like 1 Leads to Reduced MEF2C Protein 
Levels 
 
Co-transfection of MEF2C and MAML1 in HEK293 cells resulted in decreased 
MEF2C protein levels 48 h post transfection compared to MEF2C alone. MEF2C 
expressed alone had a darker band, indicating more protein is present.  Lane 3 of Figure 3 
A shows a visible decrease in the intensity of MEF2C when co-transfected with MAML1.  
These results are consistent with preliminary data produced by our lab and this suggests 
that MAML1 was able to induce degradation of MEF2C in our over-expressed cell 
culture system. 
 
  
Figure 3.  MAML1 induced degradation of MEF2C.  HEK293 cells transfected with 
MEF2C alone, MAML1 alone, and MEF2C and MAML1 together.  (A) Western blot of 
HEK293 protein samples, stained for Myc tagged MAML1, Myc tagged MEF2C, and 
GAPDH. (B) Densitometry analysis of A. MEF2C protein levels are quantified and 
normalized to GAPDH.  MEF2C alone is normalized 100 and all other samples are 
shown as a percent of the original.  Representative of 5 independent experiments. 
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Both TADs of Mastermind-like 1 are Required for Degradation to Occur 
 To determine which domains of MAML1 are required to induce degradation of 
MEF2C,  MEF2C expression plasmid were co-transfected with two MAML1 deletion 
constructs, MAML1 1-301 and MAML1 D75-300.  MAML1 1-301 contains the first 301 
amino acids, lacking the C terminus TAD2 and acidic domain 2.  MAML1 D75-300 has 
amino acids 75-300 deleted, lacking TAD1 and the first acidic domain (Figure 4). 
      
Figure 4.  MAML1 deletion construct deficient in TAD1 or TAD2.  MAML1 1-301 
contains the N terminal basic domain and acidic domain 1 along with TAD1. MAML1 
D75-300 has the N terminal basic domain and acidic domain 2, but has a TAD1 deletion. 
 
 
Neither deletion construct induced degradation of MEF2C to the levels of wild type 
MAML1.  However, MAML1 D75-300 consistently showed a decrease in MEF2C 
protein levels compared to MAML1 1-301.  These results suggest that regions within 
both TADs are required to induce full degradation of MEF2C.  Interestingly, co-
transfection with MAML1 1-301 showed an increase in MEF2C protein levels above that 
of MEF2C alone.  While this phenomenon may have been due to transfection error, it is 
possible that TAD1 of MAML1 stabilized overexpressed MEF2C.  
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Figure 5.  Co-expression of MEF2C with MAML1 deletion constructs.  HEK293 cells 
transfected with MEF2C alone, MEF2C and wild type MAML1, MEF2C with MAML1 
1-301, and MEF2C with MAML1D75-300.  (A) Western blot stained for Myc tagged 
MAML1 constructs, HA tagged MEF2C, and GAPDH. (B) Densitometry of analysis of 
A. MEF2C protein levels normalized to GAPDH first.  Represents 1 experiment. 
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MAML3 could also induce degradation of MEF2C in vitro.  HEK293 cells transfected 
with MEF2C in the presence and absence of MAML2 did not show reduced MEF2C 
levels, indicating MAML2 may not be capable of eliciting the same functions as 
MAML1.  Co-expression of MEF2C with MAML3 has shown inconclusive results.  In 
some experiments, MAML3 appeared to induce complete degradation of MEF2C, more 
so than we have seen with MAML1.  However, in recent experiments MAML3 has 
shown no ability to induce degradation of MEF2C.  These contradicting results have not 
allowed us to conclude whether MAML2 or MAML3 are capable of inducing 
degradation of MEF2C. 
 
 
Figure 6.  MAML2 and MAML3 do not induce degradation of MEF2C.  MEF2C 
expressed alone or with MAML1, MAML2, or MAML3.  (A) MAML1 shows 
degradation of MEF2C; however, when MEF2C is co-expressed with MAML2 and 
MAML3 we do not see degradation occurring. GAPDH is a loading control.  (B) 
Quantification of MEF2C protein levels by densitometry analysis. Representative of 3 
independent experiments. 
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MG132 Treatment Recovers MEF2C Protein Levels 
Inhibition of the 26s proteasome in HEK293 cells transfected with MEF2C and 
MAML1 with MG132 treatment shows increased protein levels compared to DMSO 
controls.  In order to determine whether MAML1 is facilitating the degradation of 
MEF2C through the ubiquitin- proteasome pathway, we treated samples with 10 µM 
MG132.  If MEF2C is being ubiquitinated and targeted to the proteasome, by inhibiting 
this pathway we would expect to see an increase in MEF2C protein levels via Western 
blot analysis.  HEK293 cells expressing MEF2C alone showed an increase in MEF2C 
protein levels when treated with MG132 (Figure 7).  Cells co-expressing MEF2C and 
MAML1 showed increased MEF2C expression when treated with MG132 compared to 
cells expressing MEF2C and MAML1 treated with DMSO.  However, MG132 did not 
fully prevent MAML1 induced degradation because MEF2C protein levels are still lower 
than that of MEF2C alone, both with and without MG132 treatment.  MAML1 is 
regulated through the ubiquitin proteasome pathway and is therefore a good control to 
indicate whether MG132 is effectively working (43).  MAML1 was stabilized by MG132 
treatment, indicating MG132 treatment effectively inhibited protein degradation through 
the 26S proteasome (Figure 7 A). 
HEK293 cells transfected with MEF2C and MAML2 or MAML3 showed 
increased protein levels after MG132 treatment.  Despite seeing minimal degradation 
when co-expressed with MAML2 and MAML3, MG132 treatment was still capable of 
stabilizing MEF2C protein levels (Figure 7). 
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Figure 7.  MG132 treatment recovers MEF2C protein levels.  (A) Samples containing 
MEF2C alone and MEF2C and MAML1 treated with MG132 show an increase of 
MEF2C protein levels.  (B) Densitometry analysis of MEF2C protein levels in A, 
normalized to GAPDH show MG132 treatment recovers MEF2C.  Representative of 3 
independent experiments.  (C) MEF2C expressed alone or with MAML1, MAML2, or 
MAML3.  Untreated samples containing MEF2C co-expressed with MAML1, MAML2, 
and MAML3 show a shift in molecular weight.  Treatment with MG132 increases 
MEF2C protein levels and shows a slight reduction in molecular weight.  
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Detection of Ubiquitin on MEF2C 
 To confirm MEF2C is being ubiquitinated and targeted to the 26s proteasome we 
immunoprecipitated (IP) MEF2C to determine if we could detect HA-tagged ubiquitin as 
a covalent modification.  HEK293 cells transfected with varying combinations of Myc-
MEF2C, Myc-MAML1 and HA-ubiquitin were immunoprecipitated for Myc and western 
blotted for both Myc and HA.  HA-ubiquitin was detected in both MEF2C alone and 
MEF2C with MAML1 protein extracts treated with MG132.  Samples treated with 
MG132 showed a distinct HA-ubiquitin band at the same molecular weight as MEF2C.  
However, HA-ubiquitin was not detectable on untreated MEF2C samples. 
 
 
Figure 8. Detection of ubiquitin on MEF2C treated with MG132.  Immunoprecipitation 
of MEF2C with and without MAML1.  Samples treated with MG132 show a distinct 
band at the same molecular weight of MEF2C in the HA-stained western blot.  We also 
detect HA-Ubiquitin on MAML1, which has been previously shown to be ubiquitinated. 
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To determine whether MAML1 facilitates the ubiquitination of MEF2C, Myc-
MEF2C IPs with and without MAML1 were compared.  48 Hours post-transfection there 
was no noticeable difference in the amount of ubiquitin detected on MEF2C with 
overexpressed MAML1 compared to MEF2C alone.  MAML1 may still be responsible 
for enhancing the ubiquitination of MFE2C, but there may not be a detectable difference 
at 48 hrs.  To confirm this, IP’s should be performed at varying time points post 
transfection and the ubiquitin levels should be compared over time. 
Mastermind Does Not Induce Degradation of MEF2C in Colorectal Cancer Cells 
 To determine whether MAML1 induces the degradation of native MEF2C, the 
colorectal cancer cell line HCT116 was used.  HCT1116 cells stably express MEF2C, 
allowing us to over express MAML1 and determine the effects on endogenous MEF2C.  
HCT116 cells transfected with MAML1 showed no detectable decrease in the amount of 
MEF2C present when normalized to GAPDH (Figure 9).  MG132 treatment did increase 
MEF2C levels, indicating native MEF2C is degraded through the proteasome, despite the 
inability of MAML1 to induce degradation. 
	 28	
 
Figure 9.  MAML1 does not induce degradation of MEF2C in HCT116 cells.  (A) 
HCT116 cells transfected with MAML1 and western blotted for MEF2C, Myc- MAML1, 
and GAPDH.  (B) Densitometry quantification of A shows MG132 treatment increases 
MEF2C protein levels, however MAML1 expression does not show degradation of 
MEF2C. Representative of 3 independent experiments. 
 
Similar to experiments performed with overexpressed MEF2C, the MAML1 
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stability. 
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Figure 10.  MAML1 deletion constructs are unable to induce degradation of native 
MEF2C.  (A) HCT116 cells transfected with wild type MAML1, MAML1 1-301, or 
MAML1 D75-300. Show no reduction in MEF2C protein levels.  (B) Densitometry 
analysis of MEF2C protein levels in A normalized to GAPDH. Represents 1 experiment. 
 
MAML2 and MAML3 were tested for their ability to induce degradation of 
endogenous MEF2C.  There was no distinguishable difference in MEF2C protein levels 
MAML1 1-301 
MAML1 ∆75-300 
  
MAML1 
- - + - 
- - - + 
- + - - 
MEF2C 
MAML1 
GAPDH 
MAML1 ∆75-300 
MAML1 1-301 
A 
0
20
40
60
80
100
120
140
160
EV MAML1 MAML1	1-301 MAML1	∆75-
300 
Re
la
tiv
e	I
nt
en
sit
y	t
o	
GA
PD
H
B 
	 30	
in the presence of MAML2 or MAML3.  However, samples that were treated with 2.5 
µM MG132 did show an increase in MEF2C, consistent with what was previously seen.   
Indicating endogenous MEF2C is still likely being degraded through the ubiquitin- 
Proteasome pathway. 
 
 
Figure 11.  MAML2 and MAML3 are unable to induce degradation of MEF2C in 
HCT116 cells.  (A) HCT116 cells transfected with MAML1, MAML2, and MAML3 
show no reduction in MEF2C protein levels, determined by western blot.  Cells treated 
with MG132, regardless of MAML expression, show an increase in MEF2C protein 
levels.  (B) Densitometry analysis of MEF2C levels in HCT116 cells. Represents 1 
experiment. 
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MEF2C Mutants Do Not Prevent MAML1 Induced Degradation 
Serine 98 (S98) and serine 110 (S110) in MEF2C were previously suggested as 
potential phosphorylation sites responsible for the ubiquitination of MEF2C (37, 38).  To 
identify if S98 and S110 play a role in MAML1’s ability to induce degradation of 
MEF2C we mutated them to alanine (MEF2C S98A S110A).  HEK293 cells transfected 
with MEF2C S98A S110A showed increased stability compared to wild type MEF2C.  
Although when co-expressed with MAML1, MEF2C S98A S110A was still degraded.  
Indicating MAML1 does not rely on S98 or S110 to induce degradation of MEF2C. 
 
Figure 12.  MAML1 can induce degradation of MEF2C S98A S110A.  (A) HEK293 
cells transfected with wild type MEF2C or MEF2C S98A S110A when co-expressed with 
MAML1 still show a reduction in MEF2C protein levels.  (C) Quantified MEF2C protein 
levels by densitometry analysis normalized to GAPDH.  Representative of a single 
experiment.  
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MEF2Luc and renilla with varying combinations of MEF2C and MAML1.  Cells were 
treated with MG132 or DMSO 24 hours post transfection to determine if inhibiting the 
degradation pathway increases activity of the target promoter.  We found that samples 
treated with MG132 showed a significantly larger fold change in activation of the target 
promoter (Figure 13).  Additionally, we see an increase in activation in samples 
containing MAML1 treated with MG132.  Because MAML1 is degraded through the 
ubiquitin- proteasome pathway, MG132 treatment increases the level of both MEF2C and 
MAML1 in the sample and therefore drastically increasing activation of the MEF2Luc 
promoter. 
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Figure 13.  Effects on MEF2 target promoter activity.  (A) Luciferase assay of MEF2Luc 
promoter activity. Displayed as fold change compared to MEF2Luc + pRL samples only. 
Samples treated with MG132 show a large increase in promoter activity, suggesting 
MEF2C and MAML1 were not degraded.  Represented as averages of 3 experiments.  (B) 
Luciferase assay monitoring MEF2Luc promoter activity using wild type MEF2C, 
MEF2C S98A, MEF2C S110A, and MEF2C S98A S110A.  Represented as averages 
from 3 independent experiments. 
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DISCUSSION 
Understanding the mechanisms that regulate transcription factors is an important 
aspect to understanding gene expression, development pathways, and disease 
progression.  Many diseases, including numerous types of cancer, develop as a result of 
abnormalities in gene expression (12, 29, 44).  The ubiquitin-proteasome pathway is 
exceptionally important in maintaining basal levels of gene expression through the 
degradation of unneeded transcription factors.  This process allows for increased 
sensitivity in response to external and internal signals, by limiting the response time of 
target transcription.  MAML1 plays a critical role in the co-activation and regulation 
across multiple signaling pathways.  Developing a better understanding of MAML1’s 
function in MEF2C signaling will allow us to better understand its relationship to other 
processes. 
Our results indicate MAML1 facilitates the degradation of overexpressed 
MEF2C.  Here we that show co-expression of MEF2C with MAML1 results in increased 
degradation of MEF2C.  Taken together with the cyclohexamide pulse chase data 
previously generated by our lab, we can conclude MAML1 is responsible for MEF2C’s 
increased rate of degradation.  The specific domain required to induce degradation of 
MEF2C has not yet been identified.  We show that both TAD1 and TAD2 are required 
for full degradation to occur.  However, co-expression of MEF2C with MAML1 lacking 
TAD1 (MAML1 D75-300) showed decreased protein levels compared to MAML1 1-301 
(Figure 5).  This suggests that TAD1 and TAD2 do not evoke the same response on 
MEF2C and TAD1 may be important in stabilizing protein levels.  Fryer et al. previously 
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showed MAML1 lacking the C-terminus is unable to bind CDK8 and induce degradation 
of NICD, confirming that TAD2 is required for degradation to occur (10).  Because we 
see the same trend in MEF2C, it is possible that MAML1’s association with CDK8 may 
be responsible for phosphorylation-dependent degradation of MEF2C. However, we were 
unable to determine if MAML1 increases the amount of ubiquitin detected on MEF2C. 
MEF2C is ubiquitinated and degraded by the 26S proteasome.  It is important to 
note that ubiquitin is not detectable on samples not treated with MG132. This may be 
because overexpression of ubiquitin concurrent with overexpression of MEF2C can 
increase the amount of ubiquitination occurring and therefore increase the rate of 
degradation in untreated samples.  Inhibiting the proteasome allows us to detect HA-
ubiquitin on MEF2C.  While our results confirm that MEF2C is ubiquitinated and being 
degraded by the proteasome, we saw no detectable difference in the level of ubiquitin 
detected on MEF2C in the presence of MAML1.  However, we did see recovery of 
MEF2C protein levels in the presence of MAML1 when treated with the proteasome 
inhibitor, MG132.  Taken together, these results indicate that MAML1 is likely 
facilitating the ubiquitin-dependent degradation of MEF2C. However, we are unable to 
detect a noticeable difference in ubiquitin levels 48 hours post transfection.   
Despite confirming that MEF2C is ubiquitinated, we were unable to support 
previous data suggesting serine 98 and 110 are the primary targets of phosphorylation-
dependent ubiquitination (37, 38).  While S98 and S110 may be essential for the turnover 
of MEF2C in response to cell cycle cues, our results show that it does not prevent 
MAML1-induced degradation (37).  This suggests that MAML1 may be inducing 
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degradation of MEF2C in response to alternate cellular signals.  Interestingly, no 
promoter studies have been published with MEF2C S98 and S110 mutants.  Our results 
show that the MEF2C double mutant is unable to activate transcription of the target 
promoter compared to wild type controls.  If degradation was prevented by S98A and 
S110A mutations, we would expect to see an increase in promoter activity over wild type 
MEF2C.  Alternatively, S98 and S110 may be involved in activation of the target 
promoter and unable to initiate transcription.  Though we are uncertain of the cause of 
this phenomenon, S98A and S110A mutations completely reduce activation of the MEF2 
target promoter.  Further studies need to be performed to identify the function of S98 and 
S110 in MEF2C-targeted transcription.  
While most of our studies used MEF2C expression plasmids in HEK293 cells, we 
wanted to confirm our results in cells expressing native MEF2C.  The colorectal cancer 
cell line, HCT116, stably expresses MEF2C.  Unlike HEK293 cells transfected with 
MEF2C, HCT116 cells overexpressing MAML1 did not show decreased native MEF2C 
protein levels.  We can speculate that HCT116 cells already express low levels of 
MAML1, therefore over expression of the protein does not have an effect on MEF2C 
stability.  One way to confirm that MAML1 has no effect on native MEF2C would be to 
perform an siRNA knock down of MAML1 in HCT116 cells and determine if 
reconstituted MAML1 is capable of inducing degradation.  Despite MEF2C being 
consistently expressed in HCT116 cells, it does not indicate that the signaling pathway 
responsible for assembly of the MEF2C transcriptional complex is always active.  
Therefore, MAML1-induced degradation of MEF2C may rely on an additional stimulus 
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to allow for transcription of MEF2C target genes and ultimately increased regulation of 
the transcription factor. 
It is possible that MEF2C may be a more ubiquitous transcription factor, 
functioning across multiple regulatory pathways than it was originally implicated in.  The 
protein interactions associated with MEF2C during a specific cellular event may be 
responsible for determining the mechanism of degradation.  Therefore, MEF2C may have 
multiple pathways regulating its turnover.  More studies need to be done to determine the 
functionality and specificity of MEF2C regulation across various cellular events and 
signals.  Ultimately, our results indicate that MAML1 induces degradation of MEF2C in 
a proteasome-dependent degradation pathway independent of S98 and S110 in MEF2C.  
However, we have yet to identify additional co-factors in the transcriptional complex 
required for this association to occur. 
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